Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs
15 Février 2023 - 7:00AM
Ipsen, Université de Montréal and IRICoR broaden existing oncology
partnership, with an exclusive license agreement and two new
discovery-stage programs
Ipsen, Université de Montréal and
IRICoR broaden existing
oncology partnership,
with an exclusive
license agreement and two new
discovery-stage programs
- Ipsen will now lead all
development and commercialization activities of the licensed
asset
- Ipsen, Université de
Montréal and IRICoR will continue their partnership with a further
collaboration and option to license agreement for two new oncology
discovery-stage programs
PARIS,
FRANCE,
MONTREAL, CANADA
15 February
2023 – Ipsen (Euronext: IPN; ADR: IPSEY),
Université de Montréal and IRICoR announce that Ipsen has exercised
its option to acquire exclusive rights to a pre-clinical stage
program with potential oncology applications. This license
agreement is the result of a fruitful collaboration established
between Ipsen, Université de Montréal and IRICoR in May 2020. Ipsen
will now assume all development activities and commercialization of
the drug candidate globally. Under the terms of the license
agreement the Université de Montréal will receive an upfront
payment and will be eligible to additional development and
commercial milestones, as well as royalties on net sales.
“At Ipsen we believe great partnerships create
great possibilities,” said Christelle Huguet SVP, Head of REED,
Research, External Innovation & Early Development at Ipsen. “We
are energized to take this investigational treatment forward in its
development journey, determining its potential across a number of
solid tumors and hematological cancers.”
In addition, Ipsen, Université de Montréal and
IRICoR are announcing they are further expanding their strategic
partnership by entering into a new multi-year collaboration and
option agreement for two discovery-stage programs in oncology.
Under the terms of the new collaboration and option agreement, the
team of interdisciplinary drug discovery scientists at the
Institute for Research in Immunology and Cancer (IRIC) at the
Université de Montréal will be responsible for the identification,
synthesis, and advancement of high-quality therapeutic compounds up
to drug candidate stage. Ipsen will pay the Université de Montréal
an upfront payment and research funding for two compounds that
reach the drug candidate stage. Should Ipsen decide to exercise the
option, Ipsen would assume all development activities and
commercialization of drug candidates globally. Additionally, the
Université de Montréal would receive further payments if key
development, and commercial milestones are met, and will also be
entitled to mid-single to up to low double-digit-tiered royalties
for any product commercialized.
“Given Ipsen’s established expertise in oncology
we believe they are a fantastic partner to advance the development
of this promising molecule, and we look forward to another fruitful
research collaboration to advance breakthrough therapies for
patients that are underserved by current standards of care,” said
Dr. Michel Bouvier, Director General of the Institute for Research
in Immunology and Cancer at the Université de Montréal.
“The signing of the exclusive license agreement
and the initiation of a new collaboration for the discovery of new
compounds against high-value oncology targets represent a natural
expansion of our strategic partnership with Ipsen” said Claude
Larose, VP Business Development at IRICoR. “This program was
initially financed by IRICoR before the partnership with Ipsen, so
we are excited to see the recent advancement under Ipsen’s
leadership and look forward to advancing this new drug-discovery
program and if successful, entering into a subsequent license
agreement with Ipsen in order to bring these therapies to patients
and to establish more opportunities for long-term value creation”
Mr. Larose concluded.
ENDS
Ipsen
Ipsen is a global, mid-sized biopharmaceutical
company focused on transformative medicines in Oncology, Rare
Disease and Neuroscience. With total sales of €3.0bn in FY 2022,
Ipsen sells medicines in over 100 countries. Alongside its
external-innovation strategy, the Company’s research and
development efforts are focused on its innovative and
differentiated technological platforms located in the heart of
leading biotechnological and life-science hubs: Paris-Saclay,
France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has
around 5,000 colleagues worldwide and is listed in Paris (Euronext:
IPN) and in the U.S. through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information,
visit ipsen.com.
About
IRICoRDesignated as a Centre of
Excellence in Research and Commercialization (CECR) by the Canadian
government and based at the Institute for Research in Immunology
and Cancer (IRIC) of the Université de Montréal, IRICoR is a
pan-Canadian leader in the de-risking of early-stage assets in the
field of drug discovery. IRICoR's mandate is to accelerate the
discovery, development, and commercialization of novel therapies in
cancer and rare diseases. Since 2008, IRICoR has been successfully
investing in and supporting selected high-value projects in order
to rapidly translate early-stage innovation into potential new
therapies, through either co-development partnerships with the
biopharmaceutical industry or the creation of spin-off companies.
IRICoR seamlessly combines its business-related expertise with
access to industry-level drug discovery capabilities, providing
selected academic and industry projects with access to its network
of experts and cutting-edge infrastructure, including one of the
largest academia-based drug discovery unit in Canada. IRICoR's
major funding sources include the federal CECR Program, the
Ministère de l'Économie et de l'Innovation du Québec (MEI), and
collaborative partnerships with the biopharmaceutical industry. For
more information about IRICoR, visit www.iricor.ca.
About the Institute for Research in
Immunology and Cancer of the Université de MontréalAn
ultra-modern research hub and training centre located in the heart
of the Université de Montréal, the Institute for Research in
Immunology and Cancer of the Université de Montréal was created in
2003 to shed light on the mechanisms of cancer and discover new,
more effective therapies to counter this disease. The IRIC operates
according to a model that is unique in Canada. Its innovative
approach to research has already led to discoveries that will, over
the coming years, have a significant impact on the fight against
cancer. For more information about IRIC, visit www.iric.ca.
Ipsen’s Forward-looking
statements
The forward-looking statements, objectives and
targets contained herein are based on Ipsen’s management strategy,
current views and assumptions. Such statements involve known and
unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated
herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming
reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and
‘expects’ and similar expressions are intended to identify
forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen's ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés
Financiers. The risks and uncertainties set out are not exhaustive
and the reader is advised to refer to Ipsen’s 2021 Universal
Registration Document, available on ipsen.com.
Contacts |
|
Investors |
|
Ipsen: Craig Marks Vice
President, Investor Relations+44 7484 349 193 |
|
Media |
|
Ipsen: Jess Smith Head of
R&D and Global Partnering Communications +44 7557 267634
IRICoR:Alix Molinier Project
manager +1 514-343-6111 #0324
IRIC:Noémie Desbois
MackenzieManager – Communication +1 514 475 7682
|
Ioana
PiscociuSenior Manager, Global Media Relations +33 6 69 09
12 96 |
- Ipsen IRICoR Press Release 02-2023
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024